Loading…
Sanara MedTech Inc. is projected to rise to $26.98 by 2027, a +13% move from its current price of $23.82. SMTI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $23.23 | $23.84 | $24.47 | +0.09% |
| Jul 14 | $23.00 | $23.87 | $24.76 | +0.19% |
| Jul 15 | $22.84 | $23.89 | $24.99 | +0.28% |
| Jul 16 | $22.70 | $23.91 | $25.19 | +0.38% |
| Jul 17 | $22.58 | $23.93 | $25.36 | +0.47% |
| Jul 18 | $22.48 | $23.96 | $25.53 | +0.57% |
| Jul 19 | $22.39 | $23.98 | $25.68 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.39 | $23.98 | $25.68 | +0.66% |
| Week 2 | $21.90 | $24.14 | $26.60 | +1.33% |
| Week 3 | $21.57 | $24.30 | $27.37 | +2.01% |
| Week 4 | $21.32 | $24.46 | $28.06 | +2.69% |
| Week 5 | $21.12 | $24.62 | $28.71 | +3.37% |
| Week 6 | $20.95 | $24.79 | $29.33 | +4.06% |
| Week 7 | $20.80 | $24.95 | $29.93 | +4.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sanara MedTech Inc. is a medical technology company that develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. It operates in the Healthcare sector.
Its product portfolio includes CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft (FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.
The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech was incorporated in 2001 and is based in Fort Worth, Texas.
SMTI trades at $24.84 per share and operates within the Healthcare sector, with a market capitalization of $227.63M and a ranking of 3646 by market cap.
The current price aligns with the 2026 forecast average of $24.84, indicating a near-term flat outlook relative to the forecast path.
Over the full forecast horizon, the asset shows a strong long-term upside: the 2030 average price is $48.92 (min $35.77, max $72.28) with a 2030 ROI of 97%, the 2040 average is $115.44 (min $71.64, max $199.73) with a 2040 ROI of 364.8%, and the 2050 average is $278.52 (min $152.01, max $529.48) with a 2050 ROI of 1021.3%.
A major floor 31.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.6% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 16.0% above — clearing it would confirm fresh momentum.
Key SMTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SMTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.38 | Sell | $24.12 | Sell |
| MA 10 | $24.30 | Sell | $23.99 | Sell |
| MA 20 | $23.13 | Buy | $23.47 | Buy |
| MA 50 | $22.02 | Buy | $22.30 | Buy |
| MA 100 | $20.49 | Buy | $21.85 | Buy |
| MA 200 | $22.77 | Buy | $23.09 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.59 | Neutral |
| Stoch RSI (14) | 30.81 | Neutral |
| CCI (20) | 39.04 | Neutral |
| Williams %R (14) | -39.47 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 9.52 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 60.53 | Neutral |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 1.47 | Buy |
| Ultimate (7,14,28) | 56.32 | Neutral |
| Momentum (10) | 0.70 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 24.06 | Sell |
| ADX (14) | 15.18 | Neutral |
| ATR (14) | 0.57 | Info |
The near-term technical picture is bullish, with sentiment flagged as BULLISH and RSI(14) at 60. The stock is trading above the 50-day simple moving average of $21.50 and near the 200-day moving average at $23.01, indicating a generally upward drift.
Support is listed at $20.81 and resistance at $24.84, framing a constructive range for near-term moves. The 30-day price range spans from $20.47 to $30.15, illustrating a meaningful but contained fluctuation within the current uptrend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.34 | $23.82 | $33.86 | 0% | Neutral | |
| $21.58 | $26.98 | $35.63 | +13% | Neutral | |
| $24.18 | $31.05 | $42.48 | +30% | Bullish | |
| $30.37 | $39.86 | $56.06 | +67% | Bullish | |
| $33.98 | $45.46 | $65.46 | +91% | Bullish | |
| $38.26 | $52.09 | $76.55 | +119% | Bullish | |
| $40.55 | $56.12 | $84.00 | +136% | Bullish | |
| $40.73 | $57.23 | $87.10 | +140% | Bullish | |
| $44.51 | $63.46 | $98.06 | +166% | Bullish | |
| $47.64 | $68.87 | $107.94 | +189% | Bullish | |
| $67.53 | $103.93 | $172.90 | +336% | Bullish | |
| $145.76 | $249.79 | $453.31 | +949% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.34 | $23.82 | $28.98 | +0.00% |
| August 2026 | $21.74 | $25.63 | $30.99 | +7.59% |
| September 2026 | $21.89 | $25.97 | $31.74 | +1.33% |
| October 2026 | $21.69 | $25.89 | $31.92 | -0.31% |
| November 2026 | $22.19 | $26.61 | $33.06 | +2.80% |
| December 2026 | $22.47 | $27.06 | $33.86 | +1.70% |
Click any year to see its month-by-month SMTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SMTI is projected to trade between $16.34 and $33.86, averaging $23.82 — a potential gain of 0% from today's $23.82. Price action looks broadly range-bound.
Sanara MedTech Inc.'s 2027 outlook centres on $26.98, within a $21.58 to $35.63 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, SMTI could reach as high as $42.48, with a base case around $31.05 and support toward $24.18 — roughly +30% from $23.82. Momentum favours further upside here.
Expect SMTI to range from $30.37 to $56.06 through 2029. The $39.86 average target implies a +67% move from current prices. That is up +28% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The SMTI price prediction for 2030 points to an average of $45.46 (low $33.98, high $65.46) — a potential gain of +91% on today's $23.82. Momentum favours further upside here.
In 2031, SMTI is projected to trade between $38.26 and $76.55, averaging $52.09 — a potential gain of +119% from today's $23.82. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Sanara MedTech Inc.'s 2032 outlook centres on $56.12, within a $40.55 to $84.00 range. That is up +8% on the projected 2031 average. That marks a +136% change versus current levels. Momentum favours further upside here.
By 2033, SMTI could reach as high as $87.10, with a base case around $57.23 and support toward $40.73 — roughly +140% from $23.82. Buyers look set to stay in control over this stretch.
Expect SMTI to range from $44.51 to $98.06 through 2034. The $63.46 average target implies a +166% move from current prices. That is up +11% on the projected 2033 average. Momentum favours further upside here.
The SMTI price prediction for 2035 points to an average of $68.87 (low $47.64, high $107.94) — a potential gain of +189% on today's $23.82. Buyers look set to stay in control over this stretch.
In 2040, SMTI is projected to trade between $67.53 and $172.90, averaging $103.93 — a potential gain of +336% from today's $23.82. That is up +51% on the projected 2035 average. Momentum favours further upside here.
Sanara MedTech Inc.'s 2050 outlook centres on $249.79, within a $145.76 to $453.31 range. That is up +140% on the projected 2040 average. That marks a +949% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SMTI today (≈ 41.981528 SMTI) could be worth
$10,486.52
+$9,486.52 (+949%) by 2050 · US Dollar
Based on the average projected SMTI price of $249.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SMTIwould be worth at today's price.
$1,000 invested in SMTI on Jul 10, 2025 (≈ 32.605152 SMTI) would be worth
$776.65
-$223.35 (-22.3%) today · 0.78× · US Dollar
Based on a SMTI entry price of $30.67 vs. today's $23.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.84 | $958.94 | -4.1% |
| 1 month ago | $22.99 | $1,036.1 | +3.6% |
| 3 months ago | $16.53 | $1,441.02 | +44.1% |
| 6 months ago | $23.97 | $993.74 | -0.6% |
| 1 year ago | $30.67 | $776.65 | -22.3% |
| All time (5.0y) ago | $40.08 | $594.31 | -40.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SMTI forecast.
Our base-case forecast reaches $48.00 around 2031.
Implied market cap at $48.00: $439.87M
The multi-year forecast depicts a sustained uptrend with earnings-style price progress through the 2020s and into the 2030s and beyond. In 2026 the min, avg, and max are $16.34, $24.84, and $35.89 with a 0% ROI and a NEUTRAL sentiment. From 2027 onward, the averages rise to $27.99 (ROI 12.7%), $33.07 (ROI 33.1%), and $42.99 (ROI 73.1%), with the sentiment turning bullish.
By 2030 the average price is projected to $48.92 with a 97% ROI, and by 2031–2035 the averages progress to $56.98, $60.90, $61.33, and $69.20, accompanied by rising ROI figures (129.4%, 145.2%, 146.9%, 178.6%). The forecast escalates sharply into the 2040s, with a 2040 average of $115.44 and a 364.8% ROI, and reaches a 2050 average of $278.52 with a 1021.3% ROI. These figures reflect an overall bullish long-term outlook, acknowledging that forecasts are estimates and not guarantees.
Tap a question to reveal the answer.
The 2026 forecast shows min $16.34, avg $24.84, max $35.89; ROI 0%; sentiment NEUTRAL.
The forecast shows a path of rising averages after 2026, with 2027 avg $27.99 (ROI 12.7%), 2028 avg $33.07 (ROI 33.1%), and 2029 avg $42.99 (ROI 73.1%), followed by further upside into 2030 and beyond (2030 avg $48.92, ROI 97%; 2040 avg $115.44, ROI 364.8%; 2050 avg $278.52, ROI 1021.3%). The sentiment remains bullish from 2028 onward.
Yes. The forecast shows higher-price milestones, with a 2040 max of $199.73 and a 2050 max of $529.48, indicating prices well above $100 in the projection horizon.
The 30-day range is $20.47 to $30.15.
Current price is $24.84 and market cap is $227.63M. The stock ranks 3646 by market cap.
Sanara MedTech Inc. Community Discussion
0Share your Sanara MedTech Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.